Evidence map›Paper›PMID 38265627›Full record

ArticleInfectious diseases and therapy2024

Impact of Invasive Escherichia Coli Disease on Clinical Outcomes and Medical Resource Utilization Among Asian Patients in the United States.

Chao Zhuo, Bo Zheng, Kittima Wattanakamolkul, Yoshikazu Nakayama, Martin Cloutier, Marjolaine Gauthier-Loiselle, Jun Feng, David Wu, Maureen P Neary, Jeroen Geurtsen and 2 more

Open access · goldAbstract read
In one paragraph

Article in Infectious diseases and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 6 countries.

Chao ZhuoDepartment of Infectious Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
Bo ZhengInstitute of Clinical Pharmacology, Peking University First Hospital, Beijing, People's Republic of China.
Kittima WattanakamolkulJanssen Pharmaceutical K.K, Tokyo, Japan.
Yoshikazu NakayamaJanssen Pharmaceutical K.K, Tokyo, Japan.
Martin CloutierHealth Economics and Outcomes Research, Analysis Group, Inc., 1190 Avenue Des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montreal, QC, H3B 0G7, Canada.
Marjolaine Gauthier-LoiselleHealth Economics and Outcomes Research, Analysis Group, Inc., 1190 Avenue Des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montreal, QC, H3B 0G7, Canada. Marjolaine.Gauthier-Loiselle@analysisgroup.com.
Jun FengJohnson and Johnson International (Singapore) PTE. Ltd, Singapore, Singapore.
David WuJohnson and Johnson International (Singapore) PTE. Ltd, Singapore, Singapore.
Maureen P NearyJanssen Global Services, LLC, 1000 U.S. Route 202 South, Raritan, NJ, 08869, USA.
Jeroen GeurtsenBacterial Vaccines Research and Early Development, Janssen Vaccines and Prevention BV, Leiden, 2333 CN, The Netherlands.
Antoine C El KhouryJanssen Global Services, LLC, 1000 U.S. Route 202 South, Raritan, NJ, 08869, USA.
Yoshiaki GuDepartment of Infectious Diseases, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Group for Research in Decision Analysis · CAJanssen (United States) · USJohnson & Johnson (Singapore) · SGFirst Affiliated Hospital of Guangzhou Medical University · CNJanssen (Netherlands) · NLPeking University · CNThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInvasive Escherichia coli disease (IED) can lead to sepsis and death and is associated with a substantial burden. Yet, there is scarce information on the burden of IED in Asian patients.

methodsThis retrospective study used US hospital data from the PINC AI™ Healthcare database (October 2015-March 2020) to identify IED cases among patients aged ≥ 60 years. IED was defined as a positive E. coli culture in blood or other normally sterile body site (group 1 IED) or positive culture of E. coli in urine with signs of sepsis (group 2 IED). Eligible patients with IED were classified into Asian and non-Asian cohorts based on their reported race. Entropy balancing was used to create cohorts with similar characteristics. Outcomes following IED were descriptively reported in the balanced cohorts.

resultsA total of 646 Asian and 19,127 non-Asian patients with IED were included (median age 79 years; 68% female after balancing). For both cohorts, most IED encounters had community-onset (> 95%) and required hospitalization (Asian 96%, mean duration 6.9 days; non-Asian 95%, mean duration 6.8 days), with frequent admission to intensive care (Asian 35%, mean duration 3.3 days; non-Asian 34%, mean duration 3.5 days), all standardized differences [SD] < 0.20. Compared to non-Asian patients, Asian patients were more likely to be discharged home (54% vs. 43%; SD = 0.22), and less likely to be discharged to a skilled nursing facility (24% vs. 31%; SD = 0.16). In-hospital fatality rates during the IED encounter were similar across cohorts (Asian 9%, non-Asian 10%; SD = 0.01). Most E. coli isolates showed resistance to ≥ 1 antibiotic (Asian 61%; non-Asian 64%) and 36% to ≥ 3 antibiotic classes (all SD < 0.20).

conclusionIED is associated with a substantial burden, including need for intensive care and considerable mortality, in Asian patients in the USA that is consistent with that observed for non-Asian patients.

Indexed as

Antibiotic resistanceAsianBurden of illnessE. coliInvasive E. coli diseaseMedical resource utilizationSepsis

Identifiers

PMID38265627
PMCPMC10904694
OpenAlexW4391168344

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.